Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Rapid Antidepressant Improvement Secondary to Excitatory Brain Responses

NCT: NCT04276259 · COMPLETED

NCT IDNCT04276259
StatusCOMPLETED
Start Date2020-10-19
Completion2026-03-31
SponsorMarta Peciña, MD PhD (OTHER)
First posted
Last updated

Brief Summary

The central goal of this application is to demonstrate the causal contribution of reward learning signals (expected values and reward prediction errors \[RPE\]) to antidepressant responses (Aim1) by experimentally manipulating expected values using transcranial magnetic stimulation (TMS) targeting the vmPFC (Aim 2) and μ-opioid striatal RPE signal using pharmacological approaches (Aim 3).

Frequently Asked Questions

What is Rapid Antidepressant Improvement Secondary to Excitatory Brain Responses?

Rapid Antidepressant Improvement Secondary to Excitatory Brain Responses is a clinical trial registered under NCT04276259. Current status: COMPLETED.

What is the status of NCT04276259?

The current status of NCT04276259 (Rapid Antidepressant Improvement Secondary to Excitatory Brain Responses) is: COMPLETED.

When did Rapid Antidepressant Improvement Secondary to Excitatory Brain Responses start?

Rapid Antidepressant Improvement Secondary to Excitatory Brain Responses started on 2020-10-19.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.